Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo

Yaoxue Xuebao

Volumn 43, Issue 8, 2008, Pages 811-818

  Ji, Yu Bin ^a   Zhou, Jian Hua ^a   Zuo, Ming Xin ^b   You, Qi Dong ^c  

^a HARBIN UNIVERSITY OF COMMERCE   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anticancer activity; Apoptosis; Gastric adenocarcinoma BGC823 cell; Topo I inhibitor; Xenograft tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CPUY013 COMPOUND; DNA TOPOISOMERASE; OXAZOLE DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; QUINOLONE DERIVATIVE; TOPOTECAN;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE I; FEMALE; FLUOROQUINOLONES; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OXAZOLES; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TOPOTECAN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 50249113327     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Wang HK, Morros-Natschke SL. Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents [J]. Med Res Rev, 1997,17:367-425.
2. Zhang XG, Yong Z, Zhang Q, et al. Progress of clinical trial study of topotecan [J]. Chin J New Drugs Chin Rem, 2003,22:691-696.
3. You QD, He XG, Li ZY, et al. 3-Substituted quinolone derivant and its application in the pharmacy: CN, 1473827[P]. 2004-02-11.
4. He XG, You QD. Progress of studies on the topoisomerase I and its inhibitors [J]. World Pharm, 2000,21:131-135.
5. Ulivi P, Zoli W, Fabbri F, et al. Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models [J]. Neoplasia, 2005,7:152-161.
6. Tous C, Peters GJ, Ferreira CG, et al. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines [J]. Eur J Cancer, 1999,35:796-807.
7. Yu ZY, Wang SG, Zhang XH, et al. Arsenic trioxide-mediated growth inhibition in QBC939 cholangiocarcinoma cells via cell cycle arrest in association with induction apoptosis [J]. Chongqing Med J, 2003, 32:710-712.
8. Hengartner MO. The biochemistry of apoptosis [J]. Nature, 2000,407:770-776.
9. Kuniyasu H, Yohida K, Sasaki T, et al. Conjugated linoleic acid inhibits periteneal metastasis in human gastrointestinal cancer cells [J]. Int J Cancer, 2006,118:571-576.
10. Zhang X, Steiner MS, Rinaldy A, et al. Apoptosis induction in prostate cancer cells by a novel gene product, pHyde, involves caspase-3 [J]. Oncogene, 2001,20:5982-5990.
11. Kirkin V, Joos S, et al. The role of Bcl-2 family members in tumorigenesis [J]. Biochim Biophys Acta, 2004,1644:229-249.
12. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis [J]. Oncogene, 2003,22:8590-8607.
13. Scorrano L, Korsmever SJ. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members [J]. Biochem Biophys Res Commun, 2003,304:437-444.
14. Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members [J]. Biochim Biophys Acta, 2004,1644:107-113.
15. Marxsen D, Sato Y, Hio Y, et al. p53 protein expression as prognostic factor in human gastric adenocarcinoma [J]. Anticancer Res, 2002,17:2776-2780.